Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CHF 187.14 billion. The enterprise value is 203.57 billion.
Market Cap | 187.14B |
Enterprise Value | 203.57B |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
Earnings Date | Apr 29, 2025 |
Ex-Dividend Date | Mar 11, 2025 |
Share Statistics
Novartis AG has 1.90 billion shares outstanding. The number of shares has decreased by -2.73% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.90B |
Shares Change (YoY) | -2.73% |
Shares Change (QoQ) | -1.13% |
Owned by Insiders (%) | 0.12% |
Owned by Institutions (%) | 42.30% |
Float | 1.81B |
Valuation Ratios
The trailing PE ratio is 18.54 and the forward PE ratio is 13.31. Novartis AG's PEG ratio is 1.61.
PE Ratio | 18.54 |
Forward PE | 13.31 |
PS Ratio | 4.25 |
PB Ratio | 4.88 |
P/TBV Ratio | n/a |
P/FCF Ratio | 12.71 |
P/OCF Ratio | n/a |
PEG Ratio | 1.61 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.76, with an EV/FCF ratio of 13.82.
EV / Earnings | 18.81 |
EV / Sales | 4.34 |
EV / EBITDA | 10.76 |
EV / EBIT | 13.80 |
EV / FCF | 13.82 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.71.
Current Ratio | 1.04 |
Quick Ratio | 0.79 |
Debt / Equity | 0.71 |
Debt / EBITDA | 1.50 |
Debt / FCF | 1.93 |
Interest Coverage | 16.22 |
Financial Efficiency
Return on equity (ROE) is 26.28% and return on invested capital (ROIC) is 13.72%.
Return on Equity (ROE) | 26.28% |
Return on Assets (ROA) | 10.09% |
Return on Invested Capital (ROIC) | 13.72% |
Return on Capital Employed (ROCE) | 22.19% |
Revenue Per Employee | 617,654 |
Profits Per Employee | 142,597 |
Employee Count | 75,883 |
Asset Turnover | 0.51 |
Inventory Turnover | 2.20 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.80% in the last 52 weeks. The beta is 0.49, so Novartis AG's price volatility has been lower than the market average.
Beta (5Y) | 0.49 |
52-Week Price Change | +13.80% |
50-Day Moving Average | 96.63 |
200-Day Moving Average | 95.83 |
Relative Strength Index (RSI) | 53.32 |
Average Volume (20 Days) | 4,358,546 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CHF 46.87 billion and earned 10.82 billion in profits. Earnings per share was 5.32.
Revenue | 46.87B |
Gross Profit | 35.26B |
Operating Income | 14.79B |
Pretax Income | 12.36B |
Net Income | 10.82B |
EBITDA | 18.72B |
EBIT | 14.79B |
Earnings Per Share (EPS) | 5.32 |
Balance Sheet
The company has 12.10 billion in cash and 28.45 billion in debt, giving a net cash position of -16.36 billion or -8.62 per share.
Cash & Cash Equivalents | 12.10B |
Total Debt | 28.45B |
Net Cash | -16.36B |
Net Cash Per Share | -8.62 |
Equity (Book Value) | 39.99B |
Book Value Per Share | 20.21 |
Working Capital | 917.05M |
Cash Flow
In the last 12 months, operating cash flow was 15.97 billion and capital expenditures -1.24 billion, giving a free cash flow of 14.73 billion.
Operating Cash Flow | 15.97B |
Capital Expenditures | -1.24B |
Free Cash Flow | 14.73B |
FCF Per Share | 7.76 |
Margins
Gross margin is 75.22%, with operating and profit margins of 31.55% and 23.09%.
Gross Margin | 75.22% |
Operating Margin | 31.55% |
Pretax Margin | 26.37% |
Profit Margin | 23.09% |
EBITDA Margin | 39.95% |
EBIT Margin | 31.55% |
FCF Margin | 31.42% |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 3.56%.
Dividend Per Share | 3.50 |
Dividend Yield | 3.56% |
Dividend Growth (YoY) | -56.79% |
Years of Dividend Growth | n/a |
Payout Ratio | 63.85% |
Buyback Yield | 2.73% |
Shareholder Yield | 6.29% |
Earnings Yield | 5.78% |
FCF Yield | 7.87% |
Stock Splits
The last stock split was on May 7, 2001. It was a forward split with a ratio of 40.
Last Split Date | May 7, 2001 |
Split Type | Forward |
Split Ratio | 40 |
Scores
Novartis AG has an Altman Z-Score of 3.92.
Altman Z-Score | 3.92 |
Piotroski F-Score | n/a |